Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer
TAIPEI, Taiwan, February 21, 2019 /PRNewswire/ — Foresee Pharmaceuticals Co., Ltd. (6576.TWO) (“Foresee”), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg phase 3 clinical…